Key clinical point: Patients with suspected nonradiographic axial spondyloarthritis but without positive MRI signs of sacroiliitis and/or elevated C-reactive protein levels show no response to etanercept.
Major finding: Researchers observed similar clinical improvements at 16 weeks in the etanercept and placebo arms of the study.
Study details: A randomized, double-blind, placebo-controlled trial in 80 patients with suspected nonradiographic axial spondyloarthritis.
Disclosures: The study was supported by an unrestricted financial grant from Pfizer and ReumaNederland. No conflicts of interest were declared.
Rusman T et al. Arthritis Rheumatol. 2020 Dec 5. doi: 10.1002/art.41607.